| Pharmaceutical Information |
| Drug Name |
Becaplermin |
| Drug ID |
BADD_D00216 |
| Description |
Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds. |
| Indications and Usage |
For topical treatment of skin ulcers (from diabetes) |
| Marketing Status |
Prescription |
| ATC Code |
A01AD08; D03AX06 |
| DrugBank ID |
DB00102
|
| KEGG ID |
D03065
|
| MeSH ID |
D000077214
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0T5QT
|
| NDC Product Code |
63508-005; 50484-810 |
| Synonyms |
Becaplermin | Platelet-Derived Growth Factor BB, Recombinant | Platelet Derived Growth Factor BB, Recombinant | rPDGF-BB | PDGF-BB | rhPDGF-BB | Platelet-Derived Growth Factor BB | Platelet Derived Growth Factor BB | Recombinant Platelet-Derived Growth Factor BB | Recombinant Platelet Derived Growth Factor BB | Regranex |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
165101-51-9 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
